600 to 800 patients are estimated to live with Dravet syndrome across the GCC. Fewer than 200 carry molecular SCN1A confirmation, and a 200 to 400 near-term addressable cohort sits within that confirmed subset, the pool this model sizes precisely.
GCC Dravet prevalence is a derived, not directly measured, estimate. Applying the 1-in-15,700 global incidence rate to a roughly 12 million regional paediatric population yields 600 to 800 patients, the total estimated regional prevalence. SCN1A genetic testing, the diagnostic gold standard, is available at only five to six centres across the GCC, KFSH&RC, AUH, and Sidra Medicine among them, and combined they account for fewer than 200 molecularly confirmed cases, consistent with a diagnosis rate below 30 percent of true prevalence.
Within that confirmed subset sits a narrower, near-term addressable cohort. GCC launch-readiness assessment puts the actionable population at 200 to 400 patients, those already reachable through existing specialist referral pathways and NPHC exceptional-access channels, rather than a fourth, competing prevalence estimate. Regulatory access compounds the diagnostic gap: cannabidiol is not GCC-registered and moves only through exceptional narcotics import at a 35-40 percent approval rate, while stiripentol, unrestricted by narcotics classification, anchors the de-facto regional standard of care.
GCC Dravet syndrome funnel — from derived prevalence to the near-term addressable pool
| Funnel Stage | Population | Source |
|---|---|---|
| Estimated total GCC Dravet syndrome prevalence | 600-800 | 1:15,700 incidence applied to ~12M paediatric population |
| SCN1A-molecularly-confirmed subset | <200 | KFSH&RC, AUH and Sidra Medicine genetics programmes |
| Diagnosis rate of true prevalence | <30% | GCC paediatric epilepsy genetics consensus 2022 |
| Near-term addressable cohort within confirmed subset | 200-400 | GCC launch-readiness assessment |
Sources: KFSH&RC, AUH, and Sidra Medicine paediatric epilepsy genetics programmes (2022); GCC paediatric neurology network data; GCC child neurology society epidemiology data; Saudi epilepsy society paediatric registry.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Derived total prevalence (600-800, applying 1:15,700 incidence to the regional paediatric population)
- the <200 molecularly-confirmed subset
- the 200-400 near-term addressable cohort within it, not a competing total
Delivers
- 5-6 GCC centres offering SCN1A testing
- the resulting diagnosis rate below 30%
- how molecular confirmation gates NPHC exceptional-access eligibility
Delivers
- 8-sheet structure (Strategic Context, Inputs, Model, Projections, Sensitivity, References, Market Context, QC)
- formula-driven, zero hardcoded cells
- KFSH&RC/GCC paediatric neurology network source citation per step
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why SCN1A testing access, not treatment efficacy, sets the true addressable pool
- Reconciling the <200 confirmed figure against the 600-800 derived total and the 200-400 addressable cohort
- 600-800 estimated GCC prevalence, applying 1:15,700 incidence to a ~12M paediatric population
- Regional distribution across KSA, UAE, Qatar, Kuwait, Oman, Bahrain
- Fewer than 200 molecularly-confirmed cases; diagnosis rate below 30%
- SCN1A testing access limited to 5-6 regional centres
- 200-400 near-term addressable patients within the confirmed subset
- Stiripentol-anchored backbone versus restricted cannabidiol access
- Cannabidiol narcotics-import approval at 35-40%
- NPHC exceptional-access channel and case-by-case Dravet coverage
- Which assumptions move the addressable cohort most
- Scenario ranges across derived-total and confirmed-subset bases
- Patient volume by horizon under conservative, base, and aggressive scenarios
- Revenue translation inputs
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and specialist capture (E2), treatment and biomarker eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Delivered as a live Excel workbook, not a static table, with formula-driven sheets and zero hardcoded cells.
GCC Dravet syndrome sources: KFSH&RC, AUH, and Sidra Medicine paediatric epilepsy genetics programme data, the GCC paediatric neurology network, and GCC launch-readiness assessment figures. Where a derived total, a confirmed-diagnosis subset, and a near-term addressable cohort each describe the same population at different resolutions, all three are presented together, not as competing counts.
- Derived GCC prevalence (600-800) verified against the 1:15,700 incidence rate applied to the regional paediatric population
- SCN1A-confirmed subset (<200) and the diagnosis rate below 30% verified against KFSH&RC, AUH, and Sidra Medicine genetics programme data
- 200-400 near-term addressable cohort verified against GCC launch-readiness assessment figures
Frequently asked questions
Commission this model
AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC Dravet syndrome opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.